register

Medical and Science

Patients with private health insurance pay more for cancer treatment in Australia

Health Industry Hub | May 6, 2020 |

Patients with private health insurance are paying almost twice as much in out-of-pocket expenses for cancer treatment than those with no insurance, according to the authors of research published by the Medical Journal of Australia.

Researchers from the University of Western Australia have been following adults with colorectal, lung, prostate or breast cancer between 1 April 2014 and 31 April 2017.

Participants living in outer metropolitan areas experienced higher costs than participants in rural areas. Ninety-eight per cent of outer metropolitan and 95% of rural participants were out-of-pocket and the amount they paid varied between $13 and $106,140. The majority of participants’ out-of-pocket costs were due to gap payments for medical costs such as surgery, tests and doctor’s appointments.“

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“Among rural participants, mean out-of-pocket expenses were higher for men ($1,988 v $1,362 for women), for people with private health insurance ($2,455 v $1,103), and for people who were married ($2,086 v $1,297), had undergone surgery ($1,990 v $1,360), or had worked prior to being diagnosed with cancer ($2,084 v $1,298),” reported the authors, led by Professor Christobel Saunders.

“Among outer metropolitan participants, mean out-of-pocket expenses were higher for men ($5,217 v $2,247), for people with private health insurance ($4,670 v $2,510), and for those who had undergone surgery ($5,434 v $2,157), worked prior to being diagnosed with cancer ($5,471 v $2,143), resided in higher socioeconomic areas ($4299 v $1,859), or were receiving chemotherapy ($4,286 v $2,735).

“The higher out-of-pocket expenses for people with private health insurance or undergoing surgery indicate the importance of health care funding arrangements and the magnitude of the costs borne by patients,” Saunders and colleagues wrote.

“The marked variation in out-of-pocket expenses … highlights the need for easily accessible information about services, medical costs, and gap payments for all health care services.

“Problems that still need attention in the unregulated private fee-setting environment in Australia include price discrimination in some specialist sectors.

“Bundles of care for cancer treatment that would allow patients and their families to better understand and plan for expenses should be explored,” the authors concluded.


News - Pharmaceuticals

Inside the tensions shaping PBAC decision

Inside the tensions shaping PBAC decision

Health Industry Hub | September 17, 2026 |

The evolving relationship between sponsors, the Pharmaceutical Benefits Advisory Committee (PBAC) and the health technology assessment (HTA) system came under […]

More


News - MedTech & Diagnostics

GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda

GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda

Health Industry Hub | September 17, 2026 |

GenesisCare and Omico are teaming up to bring precision oncology to more patients facing incurable, advanced or poor prognosis cancers. […]

More


News - MedTech & Diagnostics

MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy

MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy

Health Industry Hub | September 17, 2026 |

The race for six seats on the Medical Technology Association of Australia (MTAA) Board is underway, with 10 candidates nominated […]

More


News - Pharmaceuticals

New breast cancer drug fills gap left by Zoladex market withdrawal

New breast cancer drug fills gap left by Zoladex market withdrawal

Health Industry Hub | September 17, 2026 |

From 1 October 2026, Diphereline (triptorelin 3.75mg) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of […]

More


This content is copyright protected. Please subscribe to gain access.